Evercore ISI analyst Gavin Clark-Gartner raised the firm’s price target on Sarepta to $185 from $139 and keeps an In Line rating on the shares, calling Elevidys’ broad label “clearly the best-case outcome” for Sarepta. The firm forecasts $3.3B in 2025 and $3.8B in 2026 peak U.S. Elevidys sales, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Sarepta price target raised to $200 from $165 at Morgan Stanley
- Sarepta (NASDAQ:SRPT) Soars on Accelerated FDA Approval for Elevidys
- Biotech Alert: Searches spiking for these stocks today
- FDA’s Sarepta decision ‘positive’ for gene therapy, STATNews reports
- Sarepta price target raised to $235 from $166 at Needham